|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...5354555657585960616263...110111» |
- p53MVA - Tara I / O
Enrollment open, Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Jan 20, 2015
P1, N=9, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016
- |||| dovitinib (TKI258) / Allarity Therap, Oncoheroes
Trial completion, Metastases: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 20, 2015
P2, N=53, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- Biopsy: Histopathological Diagnosis of Adenomyosis (clinicaltrials.gov) - Jan 18, 2015
P=N/A, N=200, Recruiting, Sponsor: Woman's Health University Hospital, Egypt
- Trial primary completion date, FDG PET: ERRICC: Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy (clinicaltrials.gov) - Jan 17, 2015
P=N/A, N=148, Recruiting, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> May 2016
- veliparib (ABT-888) / AbbVie
Enrollment change, Combination therapy, PARP Biomarker, Metastases: Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 17, 2015
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> May 2016 N=24 --> 40
- | clomifene citrate / Generic mfg.
New P4 trial: Endometrial Shedding Prior to Ovulation Induction Pilot Study (clinicaltrials.gov) - Jan 17, 2015
P4, N=50, Recruiting, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P2 trial, PARP Biomarker: A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib (clinicaltrials.gov) - Jan 17, 2015
P2, N=5, Not yet recruiting, Sponsor: University Health Network, Toronto
- || Enrollment closed, Trial primary completion date, Surgery: Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=75, Active, not recruiting, Sponsor: The Cleveland Clinic
N=24 --> 40 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Dec 2015
- ||| Trial completion, Trial primary completion date: CCS: Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=110, Completed, Sponsor: Auxogyn, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2014
- opigolix (ASP1707) / Astellas
Enrollment change: A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain (clinicaltrials.gov) - Jan 15, 2015
P2, N=912, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2014 N=600 --> 912
- sunitinib / Generic mfg.
Enrollment change: Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 15, 2015
P2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
N=600 --> 912 N=25 --> 31
- ||| Clinical: Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=500, Not yet recruiting, Sponsor: Duke University
- | Norditropin (somatropin) / Novo Nordisk
New P2 trial: Long Protocol and Growth Hormone in Poor Responders (clinicaltrials.gov) - Jan 15, 2015
P2, N=150, Recruiting, Sponsor: Woman's Health University Hospital, Egypt
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Enrollment closed: Myocet (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=87, Active, not recruiting, Sponsor: ARCAGY/ GINECO GROUP
N=25 --> 31 Recruiting --> Active, not recruiting
- buparlisib (AN2025) / Adlai Nortye
Enrollment closed, Monotherapy, Surgery, Metastases: ENDOPIK: GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 15, 2015
P2, N=56, Active, not recruiting, Sponsor: ARCAGY/ GINECO GROUP
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion, HEOR: CervixLimburg: Analysis of the Results of Treatment for Cervical Carcinoma in Limburg (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=220, Completed, Sponsor: Maastricht Radiation Oncology
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- veliparib (ABT-888) / AbbVie
Trial primary completion date, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Jan 13, 2015
P1, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Enrolling by invitation --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- ||| paclitaxel / Generic mfg.
Biomarker, Trial completion: Pharmacogenomics of Paclitaxel in Ovarian Cancer (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=93, Completed, Sponsor: University of Southern Denmark
Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed
- |||| Preclinical, Trial primary completion date: Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (clinicaltrials.gov) - Jan 12, 2015
P3, N=1106, Recruiting, Sponsor: Finox AG
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jun 2015
- ||| Clinical: Lymph Node Counts in Endometrial Cancer Staging (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=120, Recruiting, Sponsor: Duke University
- |||||||||| New P3 trial: Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation (clinicaltrials.gov) - Jan 12, 2015
P3, N=534, Completed, Sponsor: GeneScience Pharmaceuticals Co., Ltd.
- Trial primary completion date: PISH-2: A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (clinicaltrials.gov) - Jan 12, 2015
P1, N=20, Recruiting, Sponsor: ThermalCore Inc
Trial primary completion date: Oct 2015 --> Jun 2015 Trial primary completion date: Jun 2017 --> Jun 2018
- Trial completion, Enrollment change, Trial primary completion date, Metastases, Biopsy: Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=74, Completed, Sponsor: Women and Infants Hospital of Rhode Island
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Dec 2012 --> May 2014
- |||| Preclinical, Trial primary completion date: Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (clinicaltrials.gov) - Jan 8, 2015
P3, N=1106, Recruiting, Sponsor: Finox AG
Active, not recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Dec 2012 --> May 2014 Trial primary completion date: Dec 2014 --> Oct 2015
- Enrollment change, Trial withdrawal, Trial primary completion date: Comparison of Alternative Embryo Culture Systems (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=0, Withdrawn, Sponsor: Bruce Shapiro M.D.
Trial primary completion date: Dec 2014 --> Oct 2015 N=73 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2014 --> Jan 2015
- Enrollment closed: Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=140, Active, not recruiting, Sponsor: Bruce Shapiro M.D.
N=73 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2014 --> Jan 2015 Recruiting --> Active, not recruiting
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial primary completion date: Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 8, 2015
P3, N=286, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2012
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial primary completion date, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2012 Trial primary completion date: Dec 2014 --> Jun 2015
- || trebananib (AMG 386) / Amgen
Trial primary completion date, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Jan 8, 2015
P1, N=103, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- | HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment open: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) - Jan 8, 2015
P2, N=45, Enrolling by invitation, Sponsor: Genocea Biosciences, Inc.
Trial primary completion date: Dec 2014 --> Mar 2015 Not yet recruiting --> Enrolling by invitation
- |||| selurampanel (BGG492) / Novartis
Enrollment open, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Jan 8, 2015
P2, N=77, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- everolimus / Generic mfg.
Trial completion, Trial primary completion date: RAD001 in Recurrent Endometrial Cancer Patients (clinicaltrials.gov) - Jan 8, 2015
P2, N=35, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015
- ||| Clinical: PPP_2: A Parent Child Program to Prevent Adolescent Pregnancy (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=395, Completed, Sponsor: Oregon Center for Applied Science, Inc.
- cisplatin / Generic mfg., amifostine / Generic mfg.
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer (clinicaltrials.gov) - Jan 7, 2015
P1/2, N=45, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015 Trial primary completion date: Jul 2011 --> Sep 2007
- Enrollment change, Trial termination, Trial primary completion date, IO biomarker: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=7, Terminated, Sponsor: Northwestern University
Trial primary completion date: Jul 2011 --> Sep 2007 N=80 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Apr 2014; Inability to recruit study subjects
- || Enrollment closed, Trial primary completion date: CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening (clinicaltrials.gov) - Jan 6, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=80 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Apr 2014; Inability to recruit study subjects Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Apr 2015
- Enrollment change: Accuracy of Endometrial Volume Measured by VOCAL Versus Office Hysteroscopy for Diagnosis of Endometrial Polyps (clinicaltrials.gov) - Jan 5, 2015
P=N/A, N=90, Recruiting, Sponsor: Ain Shams University
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Apr 2015 N=271 --> 90
- | New P4 trial, Preclinical: There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? (clinicaltrials.gov) - Jan 2, 2015
P4, N=213, Completed, Sponsor: U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti
- Trial completion, Enrollment change, Trial primary completion date: Elizabeth Registry for Low Grade Ovarian Cancer (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
N=271 --> 90 Active, not recruiting --> Completed | N=99999 --> 60 | Trial primary completion date: Sep 2033 --> Oct 2014
- Trial primary completion date: Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial (clinicaltrials.gov) - Jan 2, 2015
P4, N=300, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed | N=99999 --> 60 | Trial primary completion date: Sep 2033 --> Oct 2014 Trial primary completion date: Mar 2015 --> Dec 2014
- Karenitecin (cositecan) / BioNumerik
Trial primary completion date: Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=27, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Mar 2015 --> Dec 2014 Trial primary completion date: Mar 2004 --> Jul 2008
- Trial primary completion date: CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=78, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Mar 2004 --> Jul 2008 Trial primary completion date: Feb 2006 --> Jan 2008
- Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Jan 2, 2015
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Feb 2006 --> Jan 2008 Trial primary completion date: Nov 2003 --> Jan 2010
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer (clinicaltrials.gov) - Jan 2, 2015
P1, N=64, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Nov 2003 --> Jan 2010 N=100 --> 64
- topotecan / Generic mfg., cisplatin / Generic mfg.
Enrollment change, Metastases: Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer (clinicaltrials.gov) - Jan 2, 2015
P1, N=11, Completed, Sponsor: Gynecologic Oncology Group
N=100 --> 64 N=60 --> 11
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - Jan 2, 2015
P1, N=31, Completed, Sponsor: Gynecologic Oncology Group
N=60 --> 11 N=53 --> 31
- || New P3 trial: The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Jan 2, 2015
P3, N=60, Completed, Sponsor: Hayat Pharmaceutical Co. PLC
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=53 --> 31 Recruiting --> Active, not recruiting
- | topotecan / Generic mfg., cisplatin / Generic mfg.
Trial completion, Metastases: Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer (clinicaltrials.gov) - Dec 31, 2014
P1, N=11, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Completed
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - Dec 31, 2014
P1, N=35, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed